Vissia Viglietta
Research Subjects
Research Interests
Vissia Viglietta has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah AlQahtani
Neurogenetics Branch, National Institute of Neurological Disease and Stroke, National Institutes of Health, Bethesda, Maryland, USA
1 shared publication - Andrea Malaspina
Department of Neuromuscular Diseases, UCL Queen Square Motor Neuron Disease Center, UCL Queen Square Institute of Neurology, University College London, London, UK
1 shared publication Andrew T.N. Tebbenkamp
Nido Biosciences, Inc., Boston, Massachusetts, USA
1 shared publication- Angela Kokkinis
Neurogenetics Branch, National Institute of Neurological Disease and Stroke, National Institutes of Health, Bethesda, Maryland, USA
1 shared publication - Carlo Rinaldi
Institute of Developmental and Regenerative Medicine, University of Oxford, Oxford, United Kingdom
1 shared publication - Christopher Grunseich
Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
1 shared publication
Latest Publications
- Open Access
- 23 May 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (13)
Protein biomarker signature in patients with spinal and bulbar muscular atrophy
Spinal and bulbar muscular atrophy (SBMA) is a slowly progressing disease with limited sensitive biomarkers that support clinical research. We analyzed plasma and serum samples from patients with SBMA and matched healthy controls in multiple cohorts, identifying 40 highly reproducible SBMA-associated proteins out of nearly 3,000 measured. These proteins were robustly enriched in gene sets of skeletal muscle expression and processes related to mitochondria and calcium signaling. Many proteins outperformed currently used clinical laboratory tests (e.g., creatine kinase [CK]) in distinguishing patients from controls and in their correlations with clinical and functional traits in patients. Two of the 40 proteins, Ectodysplasin A2 receptor (EDA2R) and Repulsive guidance molecule A (RGMA), were found to be associated with decreased survival and body weight in a mouse model of SBMA. In summary, we identified what we believe to be a robust and novel set of fluid protein biomarkers in SBMA that are linked with relevant disease features in patients and in a mouse model of disease. Changes in these SBMA-associated proteins could be used as an early predictor of treatment effects in clinical trials.
- 23 May 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (13)
Open AccessProtein biomarker signature in patients with spinal and bulbar muscular atrophy
Spinal and bulbar muscular atrophy (SBMA) is a slowly progressing disease with limited sensitive biomarkers that support clinical research. We analyzed plasma and serum samples from patients with SBMA and matched healthy controls in multiple cohorts, identifying 40 highly reproducible SBMA-associated proteins out of nearly 3,000 measured. These proteins were robustly enriched in gene sets of skeletal muscle expression and processes related to mitochondria and calcium signaling. Many proteins outperformed currently used clinical laboratory tests (e.g., creatine kinase [CK]) in distinguishing patients from controls and in their correlations with clinical and functional traits in patients. Two of the 40 proteins, Ectodysplasin A2 receptor (EDA2R) and Repulsive guidance molecule A (RGMA), were found to be associated with decreased survival and body weight in a mouse model of SBMA. In summary, we identified what we believe to be a robust and novel set of fluid protein biomarkers in SBMA that are linked with relevant disease features in patients and in a mouse model of disease. Changes in these SBMA-associated proteins could be used as an early predictor of treatment effects in clinical trials.